BioCentury
ARTICLE | Company News

Domain Therapeutics, McGill University, University of Montreal deal

January 6, 2014 8:00 AM UTC

On Dec. 18, 2013, Domain said it partnered with McGill University and University of Montreal (UdeM) to develop biosensors using GPCR technology developed at UdeM. The technology was developed by UdeM under a grant from the Quebec Consortium for Drug Discovery (CQDM) along with AstraZeneca plc (LSE:AZN; NYSE:AZN, London, U.K.), Merck & Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.) and Pfizer Inc. (NYSE:PFE, New York, N.Y.). Under the deal, Domain gained co-exclusive access to the technology along with the pharmas. ...